Minocycline topical- BioPharmX Corporation

Drug Profile

Minocycline topical- BioPharmX Corporation

Alternative Names: BPX-01; BPX-01 1% minocycline - BioPharmX Corporation

Latest Information Update: 12 May 2017

Price : $50

At a glance

  • Originator BioPharmX Corporation
  • Class Amides; Antibacterials; Dimethylamines; Neuroprotectants; Small molecules; Tetracyclines
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Acne vulgaris; Rosacea

Most Recent Events

  • 04 May 2017 Interim efficacy and adverse events data from a phase IIb trial in Acne vulgaris released by BioPharmX
  • 29 Mar 2017 Phase-II clinical trials for Rosacea in USA (Topical) (NCT03050086)
  • 24 Mar 2017 BioPharmX completes the OPAL phase IIb trial in Acne vulgaris (In adolescents, In children, In adults) in USA (Topical) (NCT02815332)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top